25 May 2013
Keywords: Roche, Biogen Idec, Ocrelizumab, Rheumatoid arthritis
Article | 19 May 2010
In an announcement that probably comes as no surprise, Swiss drug major Roche and partner USA-based Biogen Idec have decided ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
19 May 2010
18 May 2010
24 May 2013
© 2013 thepharmaletter.com